Carfilzomib represents a novel proteasome inhibitor leveraged in the struggle against cancer. That drug operates by hindering the activity of the proteasome, a cellular machine responsible for the degradation of proteins. By inhibiting this mechanism, carfilzomib results in the accumulation of damaged or abnormal proteins, ultimately causing cell t

Tepotinib, also known as {MSC2156119|the developmental compound|this molecule), represents a promising advance in the treatment of lung problem, particularly in patients harboring MET duplications. This selective tyrosine kinase blocker|TKI demonstrates substantial efficacy against cancer progression in laboratory tests and first human evaluations.

Teclistamab serves as a revolutionary novel anti-BCMA antibody drug conjugate, designated JNJ-64007957, demonstrating immense potential in the management of multiple myeloma. This innovative medication functions by specifically binding BCMA, a molecule highly present on the surface of myeloma cells. Through this precise strategy, teclistamab admini